BridgeBio Pharma (NASDAQ:BBIO) Price Target Cut to $47.00
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price objective decreased by equities research analysts at UBS Group from $51.00 to $47.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s target price would suggest a potential upside of 70.23% from the […]
More Stories
Hurricane Watch Issued for Hawaii’s Big Island as Tropical Storm Lala Forms
By Savannah Hulsey Pointer A hurricane watch has been issued for the Big Island of Hawaii as Tropical Storm Lala...
Earnings Are Up Over 50% So Far
By Louis Navellier Through last Friday, 88% of the S&P 500 companies have announced second-quarter results. According to FactSet Earnings...
Trump Orders Navy to Replace Newer Fighter Launch System With Older Steam Catapults
By Timothy Frudd President Donald Trump ordered the Navy on Aug. 13 to return to using steam catapults to launch...
Trade Court Upholds Trump’s Shutdown of $800 De Minimis Duty Exemption
By Matthew Vadum The U.S. Court of International Trade on Aug. 13 upheld the Trump administration’s authority to end the...
Trump Says US Has ‘Total Control’ of Hormuz
By Tom Ozimek President Donald Trump said the United States has “total control” over the Strait of Hormuz, while Energy...
US Annual Inflation Rate Stabilizes in July, Slowing to 3.4 Percent
By Andrew Moran Stabilizing energy prices have helped cool off inflation pressures for the second straight month, new government data...